Abstract
Background: Group A streptococcus (GAS) is an exclusively human pathogenic bacteria. A delay in treatment of GAS infection often lead to severe diseases such as rheumatic heart disease which attributes to hundreds of thousands deaths annually. For the past few decades, the quest for a commercial GAS vaccine has been futile. Currently one of the most investigated strategies to develop vaccine against GAS includes the use of conserved epitopes from major virulent factor of GAS, M-protein.
Methods: In this study, cationic liposomes of various sizes (70 nm to 1000 nm) were prepared with dimethyldioctadecylammonium bromide (DDAB) encapsulating lipopeptide bearing M-protein derived B-cell epitope (J14). Results: Smaller liposomes induced higher antibody titres, though the differences between groups were not statistically significant. Conclusion: Nonetheless, all mice which were immunized with liposome-lipopeptide delivery system elicited high levels of systemic (IgG) and mucosal antibodies (IgA), which were discernably higher than those induced with the help of commercial adjuvant (cholera toxin B subunit).Keywords: Peptide-based subunit vaccine, mucosal immunity, liposomes, Streptococcus pyogenes, self-adjuvanting.
Medicinal Chemistry
Title:The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus
Volume: 13 Issue: 1
Author(s): Khairunnisa A. Ghaffar, Nirmal Marasini, Ashwini K. Giddam, Michael R. Batzloff, Michael F. Good, Mariusz Skwarczynski and Istvan Toth
Affiliation:
Keywords: Peptide-based subunit vaccine, mucosal immunity, liposomes, Streptococcus pyogenes, self-adjuvanting.
Abstract: Background: Group A streptococcus (GAS) is an exclusively human pathogenic bacteria. A delay in treatment of GAS infection often lead to severe diseases such as rheumatic heart disease which attributes to hundreds of thousands deaths annually. For the past few decades, the quest for a commercial GAS vaccine has been futile. Currently one of the most investigated strategies to develop vaccine against GAS includes the use of conserved epitopes from major virulent factor of GAS, M-protein.
Methods: In this study, cationic liposomes of various sizes (70 nm to 1000 nm) were prepared with dimethyldioctadecylammonium bromide (DDAB) encapsulating lipopeptide bearing M-protein derived B-cell epitope (J14). Results: Smaller liposomes induced higher antibody titres, though the differences between groups were not statistically significant. Conclusion: Nonetheless, all mice which were immunized with liposome-lipopeptide delivery system elicited high levels of systemic (IgG) and mucosal antibodies (IgA), which were discernably higher than those induced with the help of commercial adjuvant (cholera toxin B subunit).Export Options
About this article
Cite this article as:
Ghaffar A. Khairunnisa, Marasini Nirmal, Giddam K. Ashwini, Batzloff R. Michael, Good F. Michael, Skwarczynski Mariusz and Toth Istvan, The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus, Medicinal Chemistry 2017; 13 (1) . https://dx.doi.org/10.2174/1573406412666160720093138
DOI https://dx.doi.org/10.2174/1573406412666160720093138 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mean Platelet Volume During Ischemic Stroke is a Potential Pro-inflammatory Biomarker in the Acute Phase and During Neurorehabilitation Not Directly Linked to Clinical Outcome
Current Neurovascular Research Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression
Current Neuropharmacology Nutritional Programming of Foetal Development: Endocrine Mediators and Long-Term Outcomes for Cardiovascular Health
Current Nutrition & Food Science What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology Diagnosis and Management of Chronic Coronary Artery Disease
Current Cardiology Reviews Biodegradable Biomaterials
Recent Patents on Biomedical Engineering (Discontinued) Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry The Effect of Psychological Stress and Social Isolation on Neuroimmunoendocrine Communication
Current Pharmaceutical Design Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology Bisthiourea Derivatives of Dipeptide Conjugated Benzo[d]isoxazole as a New Class of Therapeutics: Synthesis and Molecular Docking Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Management of Statin-Intolerant High-Risk Patients
Current Vascular Pharmacology Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Current Medicinal Chemistry Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Pesticides-induced Cardiovascular Dysfunctions: Prevalence and Associated Mechanisms
Current Hypertension Reviews Hyperpolarized Metabolic MR in the Study of Cardiac Function and Disease
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)